Ironwood Pharmaceuticals to Host Third Quarter 2017 Investor Update Call

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2017 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 2, 2017. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 1071726. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting November 2, 2017 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on November 9, 2017. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 1071726. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed.

About Ironwood PharmaceuticalsIronwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS‐C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of a xanthine oxidase inhibitor (XOI) alone. We are also advancing a pipeline of internally and externally generated innovative product candidates in areas of significant unmet need, including uncontrolled gastroesophageal reflux disease and vascular and fibrotic diseases. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171019005190/en/

Ironwood Pharmaceuticals, Inc.
Meredith Kaya, 617-374-5082
Senior Director, Investor Relations and Corporate Communications
[email protected]

Source: Ironwood Pharmaceuticals, Inc.

You May Also Be Interested In

• This Crypto Update Just Changed the Game After ETH Jumps 18% and Pepeto Crosses $10.7M in Presale
• Core Age Rx Launches Comprehensive “Skin & Appearance” Line to Deliver Prescription-Strength, Dermatologist-Guided Skincare
• XRP Price Prediction: Can XRP Reclaim $2 After Its 20% Breakout While AlphaPepe Builds Toward Launch?